Jazz Pharmaceuticals (JAZZ) Price Target Raised to $190 at UBS
UBS maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised its price target to $190.00 (from $180.00). The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)